847417-29-2

Upstream product

• 847417-23-6 tert-butyl 4-(2-{[tert-butyl(dimethyl)silyl]oxy}-2-phenylethoxy)-3-fluorocyclohexylcarbamate 
• 847417-18-9 (2-{[4-(benzyloxy)-2-fluorocyclohexyl]oxy}-1-phenylethoxy)(tert-butyl)dimethylsilane 
• 847417-19-0 4-(2-{[tert-butyl(dimethyl)silyl]oxy}-2-phenylethoxy)-3-fluorocyclohexanol 
• 847417-22-5 4-(2-{[tert-butyl(dimethyl)silyl]oxy}-2-phenylethoxy)-3-fluorocyclohexanamine 
• 847417-17-8 2-{[4-(benzyloxy)-2-fluorocyclohexyl]oxy}-1-phenylethanol 
• 847417-24-7 tert-butyl 3-fluoro-4-(2-hydroxy-2-phenylethoxy)cyclohexylcarbamate 

Downstream Products

• 847417-30-5 tert-butyl 4-(2,2-difluoro-2-phenylethoxy)-3-fluorocyclohexylcarbamate 

Relevant academic research and scientific papers

4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.